Karyopharm Therapeutics Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $33.4 million, down from $37.9 million year-over-year, primarily due to the end of Menarini's reimbursement of development-related expenses.

U.S. XPOVIO Net Product Revenue: $30.8 million, a slight increase from $29.7 million in the prior year.

R&D Expenses: $29 million, reflecting a disciplined investment strategy.

SG&A Expenses: $25.9 million, down 9% year-over-year.

Net Loss: $67 million, compared to $37.3 million in the prior year, influenced by non-cash adjustments.

Cash Position: $65.4 million in cash and equivalents, with a warning that a $15.8 million loan payment due in September 2026 could trigger a liquidity covenant breach if not addressed.

2Strategic Updates and Business Highlights

Myelofibrosis Program: Karyopharm is advancing selinexor towards a supplemental new drug application (sNDA) under the FDA's Accelerated Approval Pathway, aiming for submission in August 2026.

SENTRY Study: Presented compelling Phase III data showing significant spleen responses and promising overall survival signals, reinforcing selinexor's potential as a treatment for myelofibrosis.

Commercial Preparedness: The company is leveraging its established hematology platform from the XPOVIO launch to facilitate a potential rapid market entry for selinexor if approved.

Multiple Myeloma Performance: Continued strong revenue from XPOVIO, with a resilient demand despite increased competition.

3Forward Guidance and Outlook

Revenue Guidance: Reaffirmed total revenue expectations for 2026 in the range of $130 million to $150 million, with U.S. XPOVIO net product revenue projected at $115 million to $130 million.

Expense Guidance: Combined R&D and SG&A expenses expected between $230 million and $245 million, with a focus on myelofibrosis and multiple myeloma.

Upcoming Milestones: Anticipated inclusion in treatment guidelines, FDA filing acceptance, and potential approval and launch of selinexor in myelofibrosis by early 2027.

4Bad News, Challenges, or Points of Concern

Declining Total Revenue: The decrease in total revenue compared to the previous year raises concerns about financial sustainability.

Increased Net Loss: The significant increase in net loss indicates ongoing financial pressures.

Debt Covenant Risk: The upcoming loan payment poses a risk of default if not managed through financing or waivers, which could impact operations.

Disappointment in Endometrial Cancer Study: The failure of the XPORT-EC-042 study to meet its primary endpoint has led to a strategic pivot away from endometrial cancer, necessitating reduced investment in that area.

5Notable Q&A Insights

sNDA Submission Details: The majority of the sNDA is prepared, with final discussions with the FDA focusing on confirmatory data from ongoing studies.

NCCN Compendia Inclusion: Inclusion is seen as critical for revenue generation, but the company aims for both NCCN listing and FDA approval to maximize market access.

Liquidity Management: The company is actively exploring financing options and engaging with lenders to enhance liquidity and extend its operational runway.

FDA Priority Review: While there is no guarantee of priority review, the company is optimistic about the strength of its submission package. This summary encapsulates Karyopharm's current financial standing, strategic direction, and the challenges it faces as it navigates critical upcoming milestones in its myelofibrosis program.